Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
1 clinical trials · Condition
◉ Watch Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (NCT01611558) | Bristol-Myers Squibb | 2012-08-21 |
Track Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line automatically
Every clearance here is in the API, with alerts when new ones post.